Segment Information (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Schedule of segment reporting information, by segment

	Three Months Ended September 30,
	2018						2017
	U.S. (1)		Outside U.S.		Total		U.S. (1)		Outside U.S.		Total
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology:
Trulicity®	$	645.9	$	170.3	$	816.2	$	412.9	$	114.8	$	527.7
Humalog®	365.6		299.0		664.6		414.9		281.3		696.2
Forteo®	182.5		208.3		390.8		234.1		207.6		441.7
Humulin®	216.9		105.1		322.1		203.0		97.5		300.5
Basaglar	157.3		43.9		201.2		115.2		30.5		145.7
Jardiance	104.2		62.7		166.9		83.8		43.4		127.2
Trajenta	50.3		85.3		135.7		68.4		84.9		153.3
Other Endocrinology	73.8		66.8		140.4		92.1		76.3		168.4
Total Endocrinology	1,796.5		1,041.4		2,837.9		1,624.4		936.3		2,560.7
Oncology:
Alimta	288.5		232.0		520.5		260.3		254.2		514.5
Cyramza®	67.0		131.4		198.4		69.5		126.5		196.0
Erbitux	132.6		26.9		159.5		136.0		27.4		163.5
Other Oncology	131.7		54.1		185.8		43.5		40.2		83.6
Total Oncology	619.8		444.4		1,064.2		509.3		448.3		957.6
Cardiovascular:
Cialis®	295.9		171.2		467.1		319.6		245.3		564.9
Effient	30.2		15.1		45.3		42.7		13.1		55.9
Other Cardiovascular	39.7		31.7		71.4		4.9		37.3		42.1
Total Cardiovascular	365.8		218.0		583.8		367.2		295.7		662.9
Neuroscience:
Cymbalta	14.5		157.5		172.0		19.6		163.5		183.2
Zyprexa®	7.0		102.8		109.9		12.6		128.0		140.6
Strattera®	10.5		88.2		98.7		52.9		84.1		137.1
Other Neuroscience	23.8		23.0		46.6		23.3		23.7		46.8
Total Neuroscience	55.8		371.5		427.2		108.4		399.3		507.7
Immunology:
Taltz®	210.6		53.3		263.9		131.3		20.0		151.3
Other Immunology	0.8		54.8		55.6		—		16.3		16.3
Total Immunology	211.4		108.1		319.5		131.3		36.3		167.6
Other pharmaceuticals	13.4		43.2		56.6		10.7		50.2		60.9
Total human pharmaceutical products	3,062.7		2,226.5		5,289.2		2,751.3		2,166.1		4,917.4
Animal health products	383.9		388.8		772.7		353.0		387.6		740.6
Revenue	$	3,446.6	$	2,615.3	$	6,061.9	$	3,104.4	$	2,553.6	$	5,658.0

	Nine Months Ended September 30,
	2018						2017
	U.S. (1)		Outside U.S.		Total		U.S. (1)		Outside U.S.		Total
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology:
Trulicity	$	1,786.5	$	487.8	$	2,274.3	$	1,090.1	$	290.7	$	1,380.8
Humalog	1,334.2		891.8		2,226.1		1,254.3		828.6		2,083.0
Forteo	529.7		608.8		1,138.5		661.5		574.3		1,235.8
Humulin	677.3		316.7		994.0		634.9		337.9		972.8
Basaglar	440.4		128.5		569.0		196.7		81.6		278.3
Jardiance	284.8		180.3		465.1		198.3		105.9		304.3
Trajenta	161.3		257.2		418.5		174.2		234.1		408.2
Other Endocrinology	199.4		206.9		406.1		283.4		228.5		511.8
Total Endocrinology	5,413.6		3,078.0		8,491.6		4,493.4		2,681.6		7,175.0
Oncology:
Alimta	815.1		760.9		1,576.0		761.9		775.4		1,537.3
Cyramza	210.7		390.1		600.8		204.3		349.2		553.5
Erbitux	394.0		81.6		475.5		398.2		78.8		477.0
Other Oncology	321.4		157.1		478.6		128.4		104.3		232.7
Total Oncology	1,741.2		1,389.7		3,130.9		1,492.8		1,307.7		2,800.5
Cardiovascular:
Cialis	954.9		546.2		1,501.2		997.3		728.5		1,725.7
Effient	59.4		45.3		104.8		290.8		35.8		326.6
Other Cardiovascular	143.7		96.3		239.7		20.5		99.6		120.2
Total Cardiovascular	1,158.0		687.8		1,845.7		1,308.6		863.9		2,172.5
Neuroscience:
Cymbalta	39.3		484.2		523.5		100.8		463.6		564.4
Zyprexa	27.6		332.8		360.4		49.3		379.6		428.9
Strattera	74.4		269.2		343.5		276.9		243.0		519.9
Other Neuroscience	72.2		71.2		143.5		88.4		72.2		160.5
Total Neuroscience	213.5		1,157.4		1,370.9		515.4		1,158.4		1,673.7
Immunology:
Taltz	495.3		135.1		630.4		343.6		43.1		386.7
Other Immunology	2.5		130.0		132.5		—		22.9		22.9
Total Immunology	497.8		265.1		762.9		343.6		66.0		409.6
Other pharmaceuticals	49.1		139.8		189.1		34.6		149.7		184.5
Total human pharmaceutical products	9,073.2		6,717.8		15,791.1		8,188.4		6,227.3		14,415.8
Animal health products	1,137.8		1,188.2		2,326.0		1,173.4		1,121.4		2,294.8
Revenue	$	10,211.0	$	7,906.1	$	18,117.1	$	9,361.8	$	7,348.7	$	16,710.6

Numbers may not add due to rounding.

⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Segment profits:
Human pharmaceutical products	$	1,514.0		$	1,242.5		$	4,751.0		$	3,765.7
Animal health products	162.6			121.9			461.9			422.6
Total segment profits	$	1,676.7		$	1,364.4		$	5,213.0		$	4,188.3
Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	1,676.7		$	1,364.4		$	5,213.0		$	4,188.3
Other profits (losses):
Acquired in-process research and development (Note 3)	(30.0		)	(205.0		)	(1,654.5		)	(1,062.6		)
Amortization of intangible assets	(153.4		)	(155.8		)	(458.7		)	(510.0		)
Asset impairment, restructuring, and other special charges (Note 5)	(83.3		)	(406.5		)	(236.0		)	(670.4		)
Other, net	1.0			(5.5		)	(7.0		)	(32.0		)
Consolidated income before taxes	$	1,411.0		$	591.6		$	2,856.8		$	1,913.3

Numbers may not add due to rounding.

Schedule of revenue from external customers and long-lived assets, by geographical areas

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Geographic Information
Revenue—to unaffiliated customers (1):
United States	$	3,446.6	$	3,104.4	$	10,211.0	$	9,361.8
Europe	1,017.0		1,017.0		3,142.9		2,877.6
Japan	608.8		616.7		1,828.9		1,767.0
Other foreign countries	989.5		920.0		2,934.3		2,704.2
Revenue	$	6,061.9	$	5,658.0	$	18,117.1	$	16,710.6

Numbers may not add due to rounding.

⁽¹⁾ Revenue is attributed to the countries based on the location of the customer.